Session Details

S045 Advanced Therapeutics for Complex Dermatologic Disease

Mon, Mar 22, 9:00 AM - 12:00 PM
3 CME Available Symposium

DESCRIPTION

The skin is a window into the inner workings of the immune system and the rest of the body. As dermatologists, we play a critical role in diagnosis and management, but often require the help of other specialties to treat complex disease. In this session, we hope to demystify the systemic therapeutics that are often used in treatment of complex skin disease, and in areas where appropriate, will demonstrate how dermatologists can reclaim the management of systemic disease.

We will also highlight research on new adverse effects for systemic medications, as well as novel treatment paradigms in our specialty.

LEARNING OBJECTIVES

1.

Develop treatment algorithms for complex medical dermatologic conditions: connective tissue diseases, hidradenitis suppurativa, GVHD, oncodermatologic conditions, and others

2.

Manage complications that may arise as a result of systemic therapeutic options prescribed by the dermatologist

3.

Discuss new understanding of pathophysiologic mechanisms that may impact adverse effects and open new treatment paradigms

DIRECTOR

Steven T. Chen, MD, MPH, FAAD

Steven T. Chen, MD, MPH, FAAD

MassGeneral Brigham/Harvard Medical School

SPEAKERS

Chia-Yu Chu, MD, IFAAD

Chia-Yu Chu, MD, IFAAD

National Taiwan University

Madeline DeWane, MD, FAAD

Madeline DeWane, MD, FAAD

Scott Elman, MD, FAAD

Scott Elman, MD, FAAD

University of Miami

Michael Stephens, MD, FAAD

Michael Stephens, MD, FAAD

Mass General Brigham

DISCLOSURES

Steven T. Chen, MD, MPH, FAAD

AbbVie – Advisory Board(Honoraria); Vertex Pharmaceuticals Incorporated – Employee (w-2 relationship)(Salary); VisualDx – Independent Contractor(Fees);

Chia-Yu Chu, MD, IFAAD

No financial relationships exist with ineligible companies.

Madeline DeWane, MD, FAAD

Veradermics Inc – Stockholder Public Company(No Compensation Received);

Scott Elman, MD, FAAD

Biogen – Consultant(Fees); Blueprint Medicines – Advisory Board(Fees); EMD Serono – Consultant (1099 relationship)(Fees); Pfizer Inc. – Investigator(Grants/Research Funding);

Michael Stephens, MD, FAAD

No financial relationships exist with ineligible companies.